Skip to main content
Premium Trial:

Request an Annual Quote

Canada s Structural Genomics Consortium Wins $95M Proteomics Grant

NEW YORK, April 3 - GlaxoSmithKline, the government of Ontario, and two regional research trusts have awarded Canada's Structural Genomics Consortium $95 million to perform proteomics studies into a number of diseases, the SGC said today.

 

The British pharma giant together with the government of Ontario Premier Ernie Eves, the Ontario Innovation Trust, and the Ontario Research and Development Challenge Fund have raised  the money to help the SGC investigate 350 human proteins links to certain cancers, neurological disorders, and infectious diseases.

 

The three-year project, which will be led by Canadian scientist Aled Edwards, involves scientists based at the University of Toronto and the University of Oxford, UK, the Wellcome Trust, Genome Canada, and Canadian Institutes of Health Research.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.